Glaukos Corporation (GKOS) Lowered to Hold at BidaskClub
BidaskClub lowered shares of Glaukos Corporation (NYSE:GKOS) from a buy rating to a hold rating in a research note published on Monday morning.
A number of other equities analysts also recently weighed in on GKOS. Zacks Investment Research raised shares of Glaukos Corporation from a hold rating to a buy rating and set a $41.00 target price for the company in a research note on Friday, August 4th. BMO Capital Markets reaffirmed a buy rating and issued a $54.00 target price on shares of Glaukos Corporation in a research note on Friday, September 1st. Stifel Nicolaus reaffirmed a buy rating on shares of Glaukos Corporation in a research note on Thursday, September 14th. Roth Capital dropped their target price on shares of Glaukos Corporation from $60.00 to $54.00 and set a buy rating for the company in a research note on Thursday, August 3rd. Finally, Piper Jaffray Companies reaffirmed a buy rating and issued a $56.00 target price on shares of Glaukos Corporation in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $49.86.
Glaukos Corporation (NYSE GKOS) opened at 32.16 on Monday. Glaukos Corporation has a 1-year low of $28.72 and a 1-year high of $52.49. The firm’s market cap is $1.11 billion. The company’s 50 day moving average is $36.92 and its 200-day moving average is $38.03.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/19/glaukos-corporation-gkos-lowered-to-hold-at-bidaskclub.html.
In related news, CEO Thomas William Burns sold 1,212 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $41.25, for a total transaction of $49,995.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Orbimed Advisors Llc sold 580,200 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $38.73, for a total transaction of $22,471,146.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 980,200 shares of company stock valued at $37,900,263. 16.40% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of GKOS. Great West Life Assurance Co. Can bought a new stake in shares of Glaukos Corporation during the first quarter worth approximately $102,000. Ameritas Investment Partners Inc. raised its stake in shares of Glaukos Corporation by 93.1% during the second quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after buying an additional 1,212 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Glaukos Corporation by 740.6% during the second quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock worth $147,000 after buying an additional 3,118 shares during the last quarter. Prudential Financial Inc. bought a new stake in shares of Glaukos Corporation during the first quarter worth approximately $204,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Glaukos Corporation during the second quarter worth approximately $262,000.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Stock Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related stocks with our FREE daily email newsletter.